Orano Enrichment USA LLC

Headquartered in Bethesda, Maryland, near the nation's capital, Orano USA has been operating in the U.S. for more than 60 years. The company is a leading technology and services provider for uranium conversion and enrichment, uranium packaging and transport, used fuel storage/packaging/transport, and federal site clean-up and closure services to the U.S. commercial and federal markets.

In the nuclear medicine field, Orano Med is developing a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), an alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells.
 

• Project IKE Enrichment, based in Tennessee, is developing a state-of-the-art uranium enrichment facility to help achieve a reliable, secure, and significant domestic fuel supply for America's nuclear energy reactors.

 

Global Orano gives nuclear energy all its value through a complete offering of products and services throughout the nuclear fuel cycle.

Orano’s purpose is to provide customers with high-performing products and services throughout the nuclear fuel cycle, thereby fully contributing to the efficient production of low-carbon nuclear energy, cancer-fighting radioisotopes, and innovative industrial applications.

Globally headquartered in Paris, with 17,500 employees worldwide, Orano includes eight primary business lines: Mining; Conversion & Enrichment; Logistics, for managing used nuclear fuel; Recycling & Nuclear Waste Management; Decommissioning & Dismantling; Nuclear Fuel Cycle Engineering; Operations Support, including radiological safety; and Nuclear Medicine.